Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2010-05-07 Major Shareholding Noti…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2010
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding for a specific instrument (AK B SE0000273294) by a holder (Länsförsäkringar Fondförvaltning AB). It quantifies the shares and voting rights before and after a transaction, noting the 'Reason for major shareholding notification Buy' and the resulting percentage crossing a threshold (implied by the structure, though the threshold itself is 10%). This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2010-05-07 English
Capital/Financing Update 2010
Capital/Financing Update Classification · 98% confidence The document is explicitly titled a "Press release" dated April 30, 2010, announcing the "publication of the prospectus for the rights offering." It details the approval of the prospectus by the Swedish Financial Supervisory Authority and outlines the mechanics, dates, and parties involved in the rights offering. This is not the comprehensive financial report (10-K or IR), nor is it a general earnings release (ER). It is an announcement about the publication of a specific offering document (the prospectus). Since the core subject is the announcement of a capital-raising activity (rights offering) and the publication of its associated documentation, the most fitting category is Capital/Financing Update (CAP). However, given the document's primary function is to announce that the prospectus *has been published* and provide details about the offering process, it strongly aligns with the intent of announcing a financing event. If the document were just the prospectus itself, it might fit CAP better, but as an announcement of the prospectus publication related to a capital raise, CAP is the best fit among the financing/capital categories. It is not a Report Publication Announcement (RPA) because it contains substantial details about the offering itself, not just a notice that a report is available. The event is a capital change/fundraising effort.
2010-04-30 English
Capital/Financing Update 2010
Capital/Financing Update Classification · 98% confidence The document is a press release dated April 30, 2010, announcing that Medivir is publishing a prospectus ('prospekt') related to a rights issue ('förtresrättsemission'). It explicitly states that the prospectus has been approved and registered by the Swedish Financial Supervisory Authority ('Finansinspektionen'). The core subject is the announcement of a financing/capital raising activity (rights issue) and the associated legal document (prospectus). This strongly aligns with the 'Capital/Financing Update' (CAP) category, as it details the terms, dates, and participants of a fundraising effort. Although a prospectus is mentioned, the document itself is the announcement of that prospectus, but the primary focus is the capital event, making CAP more specific than RPA or RNS. Since it details the structure and commitment levels of the capital raise, CAP is the best fit.
2010-04-30 Swedish
AGM Information 2010
AGM Information Classification · 99% confidence The document is explicitly titled 'Resolutions at Medivir's annual general meeting on 29 April 2010'. It details the outcomes of shareholder votes regarding the election of the board of directors, remuneration, approval of financial statements, and authorization for new share issues, all typical agenda items for an Annual General Meeting (AGM). This directly corresponds to the AGM Information category.
2010-04-29 English
AGM Information 2010
AGM Information Classification · 100% confidence The document is explicitly titled "Beslut vid Medivirs årsstämma den 29 april 2010" (Decisions at Medivir's Annual General Meeting on April 29, 2010). It details resolutions passed regarding the election of the board, remuneration, approval of guidelines for executive compensation, approval of an option program, decisions on a rights issue (capital change), authorization for future share issues, and the approval of the 2009 financial statements and discharge of liability. These topics are the core components of an Annual General Meeting (AGM) resolution summary. Therefore, the appropriate classification is AGM-R (AGM Information).
2010-04-29 Swedish
Interim / Quarterly Report 2010
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period 1 January – 31 March 2010. It contains comprehensive financial statements, including income statements, cash flow analysis, balance sheet data, and detailed management commentary on business operations, R&D portfolio, and financial position. It is not an announcement of a report, but the report itself, containing substantive financial data. Q1 2010
2010-04-29 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.